ICH Q10 defines the pharmaceutical quality system as the management system to direct and control a pharmaceutical company with regard to quality. It has four elements (monitoring, CAPA, change management, management review) and two enablers (knowledge management, quality risk management). SOPs are how the system is written down.
An assessor reads what stands behind the registration batches. By the time the first one is made, five things should be true at the receiving site: equipment and rooms qualified, analytical procedures transferred, specifications and suppliers approved, the master batch record issued and operators trained. Each needs a signed document behind it.
An ISO 9001 certificate shows that a supplier's quality management system was audited within a stated scope. It does not show that the equipment or service you bought meets your requirement. Supplier qualification assesses what you buy, against your URS, to a depth set by risk: questionnaire, audit or factory hold points.
A screenshot with no date, tag or user proves little. Evidence attached to an executed protocol should pass five checks: that it shows system, tag, date, time and user, that it is legible and uniquely referenced, that the test step cites it, that the tester signed and dated it, and that the raw data is retained.
Continued process verification is the FDA's Stage 3: assurance during routine production that the process remains in a state of control. EU GMP Annex 15 (2015) calls it ongoing process verification. Continuous process verification, defined in ICH Q8(R2), is an alternative approach to validation. Write the phrase out and cite its source.
Sampling is the fourth step of a cleaning validation. Before any swab, EU GMP Annex 15 (2015 text) expects a justified worst-case product, a carryover limit based on a toxicological evaluation, and sampling locations with recovery shown for each surface and method. Hold times belong to the run, and manual cleaning should be confirmed at a justified frequency.
Bracketing, as ICH Q1D (2002) defines it, tests only the extremes of a design factor such as strength or container size at all time points and assumes they represent the levels between. Three strengths in two bottle sizes still leave four of six combinations on test, and any reduced design should be justified.
Two ideas in ASTM E2500 shorten qualification. Subject matter experts plan, execute and review verification, and in ISPE's summary of the 2025 edition the quality unit approves the plans and the final acceptance. Vendor documentation may be used as evidence if the vendor has been assessed. EU GMP Annex 15 (2015 text) allows some FAT tests to stand at IQ/OQ where justified.
Adding a pack size to a qualified packaging line is a change. Open a change control with a regulatory assessment, check format parts and settings against the qualified range, validate where the range moved, release artwork, codes and master data, then update the packaging instructions, the line clearance checklist and operator training.
When an instrument fails its as-found check, adjusting it straight away leaves two things unasked: how long it was wrong and what relied on it. Record the as-found values, find the last calibration that passed, list what depended on the readings since, have QA assess the impact, then adjust and review the calibration interval.
The Manufacture section of CTD Module 3 is written from what the site knows: the manufacturers and their responsibilities, the batch formula, the process description with equipment type and capacity, the controls of critical steps and the process validation. Regional requirements differ; the site's job is inputs that agree with each other.
A Cpk of 1.33 puts the nearer specification limit 4 standard deviations from the process mean. It is a statistical convention: EU GMP Annex 15 (2015 text) and the FDA guidance of 2011 recommend statistical tools and name no index. With 10 batches the confidence interval is wide, so report the batch count and the interval.